CD5 and CD43 Expression are Associate with Poor Prognosis in DLBCL Patients

Area of Science:

• Hematology
• Oncology
• Immunopathology

Background:

• Diffuse large B cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
• Understanding prognostic markers is crucial for patient management and treatment strategies.

Purpose of the Study:

• To investigate the expression of CD5 and CD43 in DLBCL.
• To determine the clinical significance and prognostic value of CD5 and CD43 in DLBCL patients.

Main Methods:

• Immunohistochemistry was used to detect CD5, CD43, CD10, Bcl-6, and Mun-1 expression in 65 DLBCL patients.
• Statistical analysis correlated marker expression with clinicopathological features and patient survival.

Main Results:

• CD5 was positive in 9.2% and CD43 in 36.9% of DLBCL cases.
• CD43 expression correlated with immunophenotyping and HBV infection.
• Patients positive for both CD5 and CD43 had significantly shorter median survival times.

Conclusions:

• Positive CD5 and CD43 expression may be associated with a poorer prognosis in DLBCL.
• These markers could serve as potential prognostic indicators in DLBCL.